Patrick Cox is at it again with some teaseriffic promises — this time, we’re told that … “This is a Rare Opportunity to Own a Little-Known Biotech Company that’s Making Medical History…” Of course, nearly everything that passes through the floodgates here at Gumshoe HQ is a “rare opportunity” … otherwise, why on earth would [...]
Mark Skousen, who is one of those Ph.D-type doctors (economics) and thankfully doesn’t always insist on being called Dr. Skousen (yes, we’re looking at you Dr. Leeb), is pitching a health care stock today as a teaser for his Forecasts and Strategies newsletter. And like some folks we’ve heard from in the past, he’s teasing [...]
I’ve been getting a lot of questions about the latest “teaser video” from Patrick Cox for his Breakthrough Technology Alert — it’s the one that starts with a story about how “Robert has Alzheimer’s” and that a “breakthrough” gives him hope. And, of course, Cox will be “forced to remove” the presentation on November 11, [...]
Ian Cooper is teasing us about an options trade on a little biotech stock again — you might remember that about a year ago he and a few others were throwing out hyperactive teaser ads regarding Arena Pharmaceuticals, the company with a new weight loss drug that was on the verge of releasing results of [...]
And we’re back! Today, it’s a biotech teaser from Brian Hicks for Steve Christ’s The Wealth Advisory (we last looked at one of his a few months back, when he was predicting a big move in Geron by this Spring — that one’s still on the clock, so we’ll see). This time the tease is [...]
Dr. David Eifrig, who I’ve written about once or twice before, has stepped away from his usual Retirement Millionaire topics to write about an individual stock — well, tease us about a stock, anyway. If you’ll sign up for the good doctor’s newsletter to find out about his favorite retirement freebies and savings strategies, he’ll [...]
Now this is a nice promise: “If This Stock Doesn’t Double Between Now and June 25, I’ll Write You an Apology – Along With a Check for $1,250″ Of course, one assumes that this only applies to the folks who pony up that same $1,250 for a subscription to the Access Research Group newsletter (and, [...]
It’s been a few weeks since we looked at a teaser from Dr. Stephen Leeb, and I sure do see his name out there a lot, so I thought this one might be interesting for a quick once-over. And incidentally, yes, if you insist on using the Dr., I’ll try to remember to throw it [...]
This ad has been crashing in on Gumshoe beach in massive waves over the last week, so I thought it might be time to take a gander. It’s for the Xcelerated Profits report at Mt. Vernon Research — the last time I saw a similar ad it was from Karim Rahemtulla for this same report, [...]
I gave you a taste yesterday of the new stock teaser from Hot Stock Confidential. Now, half of that taste was probably wrong, it turns out — read this comment for a better solution than Dendreon for the “active immunity” cancer fighter, (which, you’ll recall, was clearly a guess on my part). I stand by [...]
“Move over Geron, Genentech and Osiris… The next generation in revolutionary biotechs has arrived. “(And they may be the only way to make money in this market!) “Each one of these 3 breakout stocks could realistically bring you gains of 128%, 185%, or even 422% in the next 6 months!” That heady promise introduces an [...]
Taking down Pfizer — hasn’t that already been done? At least, if you think a drop of 60% or so in share price over five years for a “blue chip” company is a “takedown.” But that’s the promise of a recent issue of the Penny Sleuth free email newsletter — and to find the details [...]
I don’t see this very often, but it looks like there’s a little battle brewing between Ian Cooper and Rob Fannon … or probably more precisely, between Stansberry & Associates and Angel Publishing. I don’t know if this has anything to do with it, but the two seem linked in several “sincerest form of flattery” [...]
Tim Fields is telling us that the next big wave will be personalized medicine, and using genetic testing to customize treatments. We’ve heard that before from several newsletter editors, and it has been an investment theme for years. Will this little stock really revolutionize medicine and lead to untold riches for investors? First, I’ve got to figure out who it is for you.
Today’s teaser ad is from Marc Lichtenfeld and his Access Group – they specialize in part on medical and biotech stocks, and the first two ads we’ve looked at them are in that area. The first one was for the “$4 Cancer Detection Device that could go to $196,” which you might remember turned out [...]
This one comes in from what looks to be a new newsletter service called “The Access Group” that will run you $2,750 a year. Phew. This is a service that they claim will enable individual investors to get access to the kind of research hedge fund companies used to pay these analysts $30,000 a year [...]
This one comes in a teaser ad for the Rising Tide Letter from Lynn Carpenter, which I’ve never looked at before. Aside from some fabulous alliteration, it offers a biotech stock that’s been picked by some high-profile biotech investors … a pick that Lynn apparently believes is a blue chip in the making. Trying the [...]
Now this is what I love about teasers: We have a newsletter editor, in this case Stephen Oakes from Volume Spike Alert, confidently assuring us that he has already chosen the best stock for the coming year … and it’s a tiny little penny stock. Delicious! And just to tease you a little bit, too, [...]
This teaser and the solution come in from our old friend Streetsifter, who has written up a few solutions in this space in the past — t0 the great appreciation of your Gumshoe. His solution has been confirmed by a few other readers who I know do a good job sniffing out solutions, so he’s [...]
Well, this is something that doesn’t happen every day: we’ve got a repeat customer for one of the stocks we teased out in the past. This is a new teaser from Karim Rahemtulla for the Xcelerated Profits newsletter, but it happens to be for a stock that was previously recommended, in a poorly timed pre-earnings [...]
